Effect of Genetic Polymorphisms on Therapeutic Response and Clinical Outcomes in Pancreatic Cancer Patients Treated with Gemcitabine

• Mackey JR , YaoSY, SmithKM et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J. Natl Cancer Inst. 91(21) , 1876–1881 (1999).
   PubMedGoogle Scholar
• Wong A , SooRA, YongWP, InnocentiF. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev.41(2) , 77–88 (2009).
   PubMed Web of Science ®Google Scholar
• Heinemann V , HertelLW, GrindeyGB, PlunkettW. Comparison of the cellular pharmacokinetics and toxicity of 2´,2´-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res.48(14) , 4024–4031 (1988).
   PubMed Web of Science ®Google Scholar
• Kocabas NA , AksoyP, PelleymounterLL et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab. Dispos. 36(9) , 1951–1959 (2008).
   PubMed Web of Science ®Google Scholar
• Huang P , ChubbS, HertelLW, GrindeyGB, PlunkettW. Action of 2´,2´-difluorodeoxycytidine on DNA synthesis. Cancer Res.51(22) , 6110–6117 (1991).
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen VW , VeermanG, VermorkenJB, PetersGJ. 2´,2´-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol.46(4) , 762–766 (1993).
   PubMed Web of Science ®Google Scholar
• Muramatsu M , SankaranandVS, AnantS et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274(26) , 18470–18476 (1999).
   PubMed Web of Science ®Google Scholar
• Bouffard DY , LaliberteJ, MomparlerRL. Kinetic studies on 2´,2´-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol.45(9) , 1857–1861 (1993).
   PubMed Web of Science ®Google Scholar
• Heinemann V , XuYZ, ChubbS et al. Cellular elimination of 2´,2´-difluorodeoxycytidine 5´-triphosphate: a mechanism of self-potentiation. Cancer Res. 52(3) , 533–539 (1992).
   PubMed Web of Science ®Google Scholar
• Fukunaga AK , MarshS, MurryDJ, HurleyTD, McLeodHL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J.4(5) , 307–314 (2004).
   PubMed Web of Science ®Google Scholar
• Plunkett W , HuangP, XuYZ, HeinemannV, GrunewaldR, GandhiV. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol.22(4 Suppl. 11) , 3–10 (1995).
   PubMed Web of Science ®Google Scholar
• Bergman AM , PinedoHM, PetersGJ. Determinants of resistance to 2´,2´-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat.5(1) , 19–33 (2002).
   PubMed Web of Science ®Google Scholar
• Bergman AM , GiacconeG, van Moorsel CJ et al. Cross-resistance in the 2´,2´-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur. J. Cancer36(15) , 1974–1983 (2000).
   PubMed Web of Science ®Google Scholar
• Nakano Y , TannoS, KoizumiK et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 96(3) , 457–463 (2007).
   PubMed Web of Science ®Google Scholar
• Achiwa H , OguriT, SatoS, MaedaH, NiimiT, UedaR. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci.95(9) , 753–757 (2004).
   PubMed Web of Science ®Google Scholar
• Li L , FridleyB, KalariK et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68(17) , 7050–7058 (2008).
   PubMed Web of Science ®Google Scholar
• Soo RA , WangLZ, NgSS et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 63(1) , 121–127 (2009).
   PubMed Web of Science ®Google Scholar
• Okazaki T , JavleM, TanakaM, AbbruzzeseJL, LiD. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res.16(1) , 320–329 (2010).
   PubMed Web of Science ®Google Scholar
• Shi JY , ShiZZ, ZhangSJ et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14(11) , 759–768 (2004).
   PubMedGoogle Scholar
• Sugiyama E , KaniwaN, KimSR et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin. Pharmacokinet. 49(8) , 549–558 (2010).
   PubMed Web of Science ®Google Scholar
• Giovannetti E , PacettiP, ReniM et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 12(12) , 1641–1652 (2011).
   PubMed Web of Science ®Google Scholar
• Yi JH , LeeJ, ParkSH et al. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology 80(3–4) , 175–180 (2011).
   PubMed Web of Science ®Google Scholar
• Therasse P , ArbuckSG, EisenhauerEA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3) , 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Huang MY , FangWY, LeeSC, ChengTL, WangJY, LinSR. ERCC2 2251A >C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer8 , 50 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis CM . Genetic association studies: design, analysis and interpretation. Brief. Bioinform.3(2) , 146–153 (2002).
   PubMedGoogle Scholar
• WHO handbook for reporting results for cancer treatment. In: WHO Offset Publication No. 48. WHO, Geneva, Switzerland, 1–45 (1975).
   Google Scholar
• Ziske C , SchlieC, GorschluterM et al. Prognostic value of CA 19–9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br. J. Cancer 89(8) , 1413–1417 (2003).
   PubMed Web of Science ®Google Scholar
• Ryu JS , ShinES, NamHS et al. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J. Thorac. Oncol. 6(8) , 1320–1329 (2011).
   PubMed Web of Science ®Google Scholar
• Spratlin J , SanghaR, GlubrechtD et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10(20) , 6956–6961 (2004).
   PubMed Web of Science ®Google Scholar
• Giovannetti E , Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res.66(7) , 3928–3935 (2006).
   PubMed Web of Science ®Google Scholar
• Osato DH , HuangCC, KawamotoM et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13(5) , 297–301 (2003).
   PubMedGoogle Scholar
• Damaraju S , ZhangJ, VisserF et al. Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenet. Genomics 15(3) , 173–182 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka M , JavleM, DongX, EngC, AbbruzzeseJL, LiD. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer116(22) , 5325–5335 (2010).
   PubMed Web of Science ®Google Scholar
• Gasperowicz M , OttoF. Mammalian Groucho homologs: redundancy or specificity? J. Cell. Biochem.95(4) , 670–687 (2005).
   PubMed Web of Science ®Google Scholar
• Jarjanazi H , KieferJ, SavasS et al. Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. Hum. Mutat. 29(4) , 461–467 (2008).
   PubMed Web of Science ®Google Scholar
• Gilbert JA , SalavaggioneOE, JiY et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12(6) , 1794–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Hansen NT , BrunakS, AltmanRB. Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol. Ther.86(2) , 183–189 (2009).
   PubMed Web of Science ®Google Scholar
• Fitzgerald SM , GoyalRK, OsborneWR, RoyJD, WilsonJW, FerrellRE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet.119(3) , 276–283 (2006).
   PubMed Web of Science ®Google Scholar

▪ Websites

• PharmGKB. www.pharmgkb.org
   Google Scholar
• PubMed. www.ncbi.nlm.nih.gov/pubmed
   Google Scholar
• Korean HapMap Project. www.khapmap.org
   Google Scholar
• International HapMap Project. http://hapmap.ncbi.nlm.nih.gov
   Google Scholar